Latanoprost for hair loss is an area of growing interest, though it remains firmly off-label in the UK. Originally licensed as an eye drop for glaucoma and ocular hypertension, latanoprost drew attention when patients reported increased eyelash growth as a side effect — prompting researchers to explore whether it might stimulate scalp hair follicles. Early pilot studies show some promise, particularly in androgenetic alopecia, but the evidence base is limited and no licensed scalp formulation exists. This article explains what the science currently shows, the safety considerations, and how to seek appropriate professional advice.

What Is Latanoprost and How Might It Affect Hair Growth?

Latanoprost is a prostaglandin F2α analogue licensed for glaucoma that may stimulate hair follicle activity by prolonging the anagen (growth) phase, based on its observed side effect of increased eyelash growth. It is not licensed for scalp hair loss in the UK.

Experiencing these side effects? Our pharmacists can help you navigate them →

Latanoprost is a prostaglandin F2α analogue licensed in the UK primarily as an eye drop preparation for the treatment of elevated intraocular pressure (IOP) in conditions such as open-angle glaucoma and ocular hypertension. According to the UK Summary of Product Characteristics (SmPC) for latanoprost eye drops (e.g., Xalatan 50 micrograms/ml), it lowers IOP primarily by increasing uveoscleral outflow of aqueous humour, thereby reducing pressure and helping to protect the optic nerve from damage. It is available on prescription and regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).

Interest in latanoprost as a potential treatment for hair loss arose largely from an observed side effect in patients using it as an eye drop: a noticeable increase in eyelash length, thickness, and pigmentation — a condition known as hypertrichosis. This observation prompted researchers to investigate whether a similar mechanism might stimulate hair follicle activity elsewhere on the scalp.

The proposed mechanism relates to prostaglandin receptors found within hair follicles. Prostaglandins are thought to play a role in regulating the hair growth cycle, which consists of three phases: anagen (active growth), catagen (transition), and telogen (resting). It is hypothesised that prostaglandin F2α analogues such as latanoprost may prolong the anagen phase and potentially influence follicles in a dormant state — though this remains an experimental concept with limited translational evidence in humans. This is particularly relevant in androgenetic alopecia (male and female pattern hair loss), where follicle miniaturisation and shortened growth cycles are central to the condition.

It is important to note that latanoprost is not currently licensed for the treatment of scalp hair loss in the UK, and no licensed scalp formulation exists. Any such use is considered off-label and should only be undertaken under the direct supervision of a specialist clinician.

Not sure if this is normal? Chat with one of our pharmacists →

Evidence Behind Latanoprost for Hair Loss

A small randomised pilot trial found statistically significant increases in hair density with topical latanoprost 0.1% over 24 weeks, but evidence remains preliminary with no NICE or MHRA endorsement for this use.

The clinical evidence base for latanoprost as a hair loss treatment remains limited, though early findings have generated genuine scientific interest. A key proof-of-concept study published in the Journal of the American Academy of Dermatology (Blume-Peytavi et al., 2012) investigated topical latanoprost 0.1% solution applied to the scalp in men with mild androgenetic alopecia. This randomised, double-blind, placebo-controlled pilot trial enrolled a small number of participants (approximately 16 men per group) over 24 weeks and found a statistically significant increase in hair density in the latanoprost group compared with placebo. Whilst these findings suggest a biologically plausible effect on follicular activity, the small sample size, short duration, and pilot nature of the study mean that results cannot be considered definitive.

It is essential to contextualise these findings carefully:

• Sample sizes in existing studies have been small, limiting the generalisability of results.

• Long-term efficacy and safety data for topical scalp application are lacking, and there are no robust head-to-head comparisons with established treatments such as minoxidil or finasteride.

• Standardised, quality-assured formulations for scalp use are not commercially available in the UK; any compounded preparation would carry additional uncertainty regarding consistency and quality.

• Studies conducted to date have focused predominantly on male androgenetic alopecia, with very limited data in women or in other hair loss conditions such as alopecia areata.

Some researchers have also explored other prostaglandin analogues, including bimatoprost, with similarly preliminary and unlicensed results for scalp use. While the mechanistic rationale is scientifically credible, neither NICE nor the MHRA has issued guidance endorsing latanoprost for scalp hair loss, and it does not feature in current NHS treatment pathways for alopecia (see NICE Clinical Knowledge Summary: Alopecia). Patients should therefore approach claims about its effectiveness with appropriate caution and seek professional advice before considering any off-label use.

Possible Side Effects and Safety Considerations

Safety data for scalp use are limited; known risks include local skin irritation, hyperpigmentation, and unintended hair growth, with a theoretical risk of systemic absorption and specific caution required in pregnancy.

Because latanoprost is not licensed for scalp use, its safety profile in this context has not been formally evaluated through large-scale clinical trials. The known side effects are largely derived from its established use as an ophthalmic preparation, and it is not fully understood how these translate to topical scalp application.

Known side effects from ophthalmic use (per UK SmPC) include:

• Changes in iris pigmentation (increased brown pigmentation), which is generally irreversible — this is an ocular effect specific to eye drop use

• Eyelid skin darkening and prostaglandin-associated periorbitopathy (periorbital fat atrophy, deepening of the upper eyelid sulcus)

• Hypertrichosis (increased hair growth around the eye area)

• Eye irritation, redness, and stinging

• Cystoid macular oedema — a particular concern in patients who are aphakic or pseudophakic with a torn posterior lens capsule

• Caution is required in patients with a history of uveitis or other inflammatory eye conditions, and in those with a history of herpetic keratitis

• Very rarely, exacerbation of asthma has been reported

Potential concerns specific to scalp application include:

• Local skin irritation and contact dermatitis, which may be partly attributable to preservatives such as benzalkonium chloride present in ophthalmic formulations

• Local skin hyperpigmentation at or near application sites — this is a general risk for all users and is not specific to any particular skin tone

• Unintended hair growth in areas where the solution inadvertently contacts skin, such as the forehead or temples

• A theoretical risk of systemic absorption, though this is considered low with topical application

Pregnancy and breastfeeding: Latanoprost should not be used for cosmetic or off-label indications during pregnancy or breastfeeding unless a specialist clinician has explicitly assessed the risks and benefits and deemed it essential. Women of childbearing age should discuss contraception and the potential risks with their clinician before use.

Patients should never use ophthalmic latanoprost preparations on the scalp without direct guidance from a qualified healthcare professional, as the concentration and excipients in eye drops are formulated specifically for ocular tissue. Care should be taken to avoid eye contact if any compounded topical preparation is applied to the scalp, and hands should be washed thoroughly after application.

If you experience any suspected side effects from latanoprost or any other medicine, you can report these directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Speaking to Your GP or Dermatologist About Hair Loss Treatment

A GP or dermatologist should be the first point of contact for hair loss; established UK treatments are topical minoxidil and oral finasteride, with latanoprost only considered under specialist supervision given its off-label status.

Hair loss can have a significant impact on self-esteem and psychological wellbeing, and it is entirely appropriate to seek professional advice if you are concerned. A GP is usually the first point of contact and can help identify the underlying cause of hair loss — which may include androgenetic alopecia, telogen effluvium, thyroid dysfunction, nutritional deficiencies, or autoimmune conditions such as alopecia areata. A thorough history, examination, and targeted investigations are typically the first steps in assessment, in line with the NICE Clinical Knowledge Summary on alopecia. Common initial tests may include thyroid function (TSH), serum ferritin, full blood count, and other tests as guided by the clinical picture (for example, B12 and folate if indicated).

You should consider speaking to your GP promptly if you notice:

• Sudden or patchy hair loss

• Hair loss accompanied by scalp inflammation, scaling, pain, burning, or loss of visible follicular openings (which may suggest scarring alopecia requiring early specialist referral)

• Suspected fungal scalp infection (tinea capitis), particularly in children

• Rapidly progressive hair loss

• Associated symptoms such as fatigue, weight changes, or skin changes

• Significant psychological distress related to hair loss

For androgenetic alopecia specifically, treatments with an established evidence base and NICE support include topical minoxidil (available over the counter for both men and women) and oral finasteride (prescription-only, licensed for men only). Finasteride carries important safety considerations: it is not suitable for women, particularly those who are pregnant or may become pregnant, as it is teratogenic to a male foetus (pregnant women should not handle crushed or broken tablets). The MHRA has also issued safety updates highlighting risks of sexual dysfunction and mood changes associated with finasteride; patients should discuss these risks fully with their GP before starting treatment. Topical minoxidil and oral finasteride remain the standard of care in the UK.

If first-line treatments are ineffective or unsuitable, referral to a consultant dermatologist may be appropriate. In specialist settings, options such as platelet-rich plasma (PRP) therapy may be discussed, though the evidence base for PRP is variable and it is not routinely commissioned on the NHS. Oral minoxidil is another off-label option that some specialists consider, with appropriate monitoring for blood pressure and other side effects.

If you are interested in latanoprost for hair loss, it is important to raise this with a dermatologist rather than attempting to source or self-administer the medication independently. A specialist can review the current evidence, assess your individual suitability, and discuss the potential risks and benefits in the context of your overall health. Informed, supervised decision-making is always preferable to unguided self-treatment, particularly with a medication that carries an incompletely understood risk profile outside its licensed indication.

Further information on hair loss causes and treatments is available from the NHS (nhs.uk/conditions/hair-loss) and the British Association of Dermatologists (bad.org.uk), which provides patient information leaflets on androgenetic alopecia and alopecia areata.

Frequently Asked Questions